Bayer, Dewpoint take aim at heart disease, women's health in deal worth up to $100M

Dewpoint Therapeutics, the biotech working to drug biomolecular condensates, has struck its first big deal. It’s teaming up with Bayer on new treatments for a pair of neglected fields: heart disease and women’s health…